CBAY - CymaBay Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5449.27M
Enterprise Value 3186.93M
Trailing P/E N/A
Forward P/E 1-4.17
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)1.74
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-2.23

Trading Information

Stock Price History

Beta (3Y Monthly) 1.54
52-Week Change 3-49.84%
S&P500 52-Week Change 37.06%
52 Week High 314.00
52 Week Low 34.82
50-Day Moving Average 38.23
200-Day Moving Average 310.62

Share Statistics

Avg Vol (3 month) 31.36M
Avg Vol (10 day) 3773.77k
Shares Outstanding 5N/A
Float 53.87M
% Held by Insiders 10.74%
% Held by Institutions 188.51%
Shares Short (Jun 28, 2019) 48.43M
Short Ratio (Jun 28, 2019) 43.59
Short % of Float (Jun 28, 2019) 412.34%
Short % of Shares Outstanding (Jun 28, 2019) 412.27%
Shares Short (prior month May 31, 2019) 47.46M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-20.71%
Return on Equity (ttm)-33.47%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-43.75M
EBITDA -83.67M
Net Income Avi to Common (ttm)-78.62M
Diluted EPS (ttm)-1.32
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)264.76M
Total Cash Per Share (mrq)3.85
Total Debt (mrq)2.41M
Total Debt/Equity (mrq)0.94
Current Ratio (mrq)18.66
Book Value Per Share (mrq)3.75

Cash Flow Statement

Operating Cash Flow (ttm)-70.89M
Levered Free Cash Flow (ttm)-49.59M